# Vertex Pharmaceuticals Incorporated  Share Price Target ‘$458.26’, now 9.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-share-price-target-458.26-now-9.3-upside-potential/4121142075
- Published: 2024-02-09T13:43:33+00:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** which can be found using ticker (VRTX) now
have 23 analysts in total covering the stock. The consensus rating is pointing to‘
buy’. The target price High/Low ranges between $578.00 and $325.00 and has a mean
share price target at $458.26. (at the time of writing). Now with the previous closing
price of $419.08 this would imply there is now a potential upside of 9.3%. There
is a 50 day moving average of $405.96 and the 200 moving average now moves to $364.28.
The company has a market capitalization of 109.02B. The current share price for 
the company is: $423.06 USD

 The potential market cap would be $119,207,278,198 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 30.48, revenue per share of $38.30
and a 13.21% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on: